ClinicalTrials.gg
Not yet recruitingNCT07093047Updated Nov 28, 2025

Effects of Italian Law 219/2017 in Pediatric Intensive Care Units

An observational study in Refusal of Treatment, sponsored by University of Padova. Not yet recruiting at 3 sites in Italy. Per ClinicalTrials.gov, last updated 2025-11-28.

Sponsored by University of Padova · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Feb 2026, 9 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
172
Sex
All
01

Study summary

This study aims to investigate pediatric intensive care providers' knowledge, perceptions, and experiences with Law 219/2017 by means of a national multicentric non-interventional cross-sectional study.

Read the detailed description

In Italy in January 2018, Law 219/2017 came into effect after years of discussion regarding the possibility of refusing potentially life-saving health treatments, with its general principles being respect of life, human dignity, and personal self-determination, and introducing the concept of Advance Care Planning, the possibility for the patient to refuse medical treatment stating also that the patient cannot demand health treatments contrary to the law, professional ethics or good clinical-care practices letting the physician protected by the law in not providing interventions that he/she judges contrary to the patient's best health interest.

This study aims to investigate pediatric intensive care providers' knowledge, perceptions, and experiences with Law 219/2017 by means of a national multicentric non-interventional cross-sectional study.

02

Conditions studied

  • Refusal of Treatment

Browse trials for

03

In context

Treatment Refusal

28 studies on the registry are indexed under Treatment Refusal; 6 are open to participants now.

This study's planned enrollment of 172 is close to the median of 188 across 13 observational studies indexed under Treatment Refusal.

Browse Treatment Refusal studies →

Lead sponsor

University of Padova is the lead sponsor of 215 studies on the registry; 39 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Healthcare personnel employed in a pediatric intensive care units

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthcare personnel employed in a pediatric intensive care units

Exclusion criteria

Exclusion Criteria:

  • None
05

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
172 participants (estimated)
Patient registry
No

Groups and cohorts

  • Healthcare personnel

    Healthcare personnel employed in pediatric intensive care units

    Other: Questionnaire administration

Interventions

  • OtherQuestionnaire administration

    Participants are required to complete a survey collecting anonymous data

06

What researchers measure

Primary outcomes

  1. Knowledge of the Italian Law 219/2017

    The level of knowledge of the Italian law 219/2017, will be assessed through a survey developed drafting questions and answers by a multiprofessional panel of international experts in PICU, Bioethics, and research methodology. This survey contains questions on the law and also personal reflections on the choices made by healthcare professionals in the case studies included. The questions will not be given a score, the data analysis will be purely qualitative.

    Time frame: Through study completion, an average of three months

  2. Experience about the application of the Italian Law 219/2017

    The questions, which were constructed by a multidisciplinary team, contain a section to explore the personal experience of the respondents during their shifts in intensive care.

    Time frame: Through study completion, an average of three months

07

Study locations

3 sites
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2025; primary completion for Feb 2026, 3 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 3, 2025
First posted
Jul 30, 2025
StartEst.
Nov 25, 2025
Primary completionEst.
Feb 2026
CompletionEst.
May 2026
Last update
Nov 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07093047
Responsible party
Sponsor
First posted
Jul 30, 2025
Start date
Nov 25, 2025 (estimated)
Primary completion
Feb 2026 (estimated)
Completion
May 2026 (estimated)
Last update
Nov 28, 2025

Study contacts

Matteo Martinato, PhD
Contact
matteo.martinato@ubep.unipd.it
+393472306806
Matteo Martinato, PhD
principal investigator · University of Padova

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion